Dermatopathia pigmentosa reticularis: disease-characteristics research report

Dermatopathia pigmentosa reticularis (DPR; MONDO:0007445) is an exceptionally rare, autosomal-dominant ectodermal dysplasia associated with heterozygous KRT14 variants. Its characteristic clinical combination is persistent reticulate skin hyperpigmentation, nonscarring alopecia, and nail dystrophy. Absence of fingerprints, palmoplantar keratoderma, and abnormal sweating are additional clues. DPR and Naegeli–Franceschetti–Jadassohn syndrome (NFJS) are closely overlapping KRT14-associated phenotypes; a family can show features of both. The evidence base consists mainly of pedigrees, individual case reports, pathology, and a related-syndrome cell experiment—not a prospective natural-history cohort. [52][21][81][65]

Evidence convention: “Human clinical” denotes observations in affected people; “in vitro” denotes cell experiments; “mouse” denotes genetically altered mice. An ontology term marked suggested is a useful annotation, not evidence that its biological process has been experimentally demonstrated in DPR.

1. Disease information

Primary genetic evidence: Lugassy and colleagues studied one DPR family and four NFJS families. Their abstract states, “Heterozygous nonsense or frameshift mutations in KRT14 were found to segregate with the disease trait in all five families.” Human pedigree and biopsy study; published online 25 August 2006, PMID 16960809, DOI 10.1086/507792, article URL. [21]

2. Etiology: causes, risks, protection, and environment

3. Phenotypes, timing, frequency, and impact

Frequency caution: The classical triad describes the DPR phenotype, but there are no defensible population-derived percentages for its individual findings. HPO-linked listings provide terms without usable DPR-specific frequencies; the appended “30” on one aggregator’s labels must not be interpreted as 30%. One 2019 review counted 21 published DPR patients, underscoring the small and selected evidence base. [185][136][65]

The 2023 case report provides a useful single-patient, not frequency, example: a 22-year-old man had pigmentation from birth, alopecia, nail dystrophy, and absent dermatoglyphics, while his teeth and sweating were normal. Pigment International 2023, 10(3):172–178; article URL; no PMID was supplied by the journal page. [76] No DPR-specific EQ-5D, SF-36, PROMIS, or comparable numerical quality-of-life results were identified in these sources.

4. Genetic and molecular information

These are the directly pertinent early variants, not an exhaustive list of KRT14 variation. In particular, an aggregator’s other KRT14 missense records should not be interpreted as proven causal variants for the DPR phenotype merely because they appear under a broadly associated gene or condition. [185][21]

Molecular interpretation: Early truncation is established at the DNA level. Reduced functional K14—haploinsufficiency—is supported by experiments in NFJS-derived research, but a 2024 DPR report explicitly notes conflicting evidence about making haploinsufficiency the complete explanation. Early mutant transcripts may escape complete nonsense-mediated decay, and an alternative downstream translation product was proposed; a dominant-negative contribution has not been conclusively excluded for every variant. No DPR-specific modifier, epigenetic signature, causative chromosomal rearrangement, somatic driver, or reliable variant-based severity predictor is established. A chromosome 1q21.1–q21.2 duplication detected in the 2024 proband was considered relevant to separate neurodevelopmental findings, not the explanation for his DPR skin phenotype. [21][web:18049449][81]

5. Environmental and infectious information

DPR is not classified as an infectious or exposure-induced disease. No causative bacteria, virus, fungus, parasite, pollutant, radiation exposure, occupational exposure, dietary pattern, smoking pattern, or alcohol exposure is established. Heat exposure matters clinically when sweating is reduced; it should be recorded as a potential symptom aggravator, not a cause of the KRT14 variant. No DPR-specific protective lifestyle intervention or validated gene–environment risk estimate is available. [52][21][252]

6. Mechanism and pathophysiology

Ordered causal chain

1. A germline heterozygous early stop-gain or frameshift in KRT14 leads to a prematurely interrupted keratin-14 coding sequence in the NFJS/DPR spectrum. Demonstrated in human families. [21]
2. The altered sequence leads to reduced effective K14 protein or altered production of a short/head-deficient product. Reduced K14 is experimentally supported for NFJS; the precise contribution of transcript decay versus alternative products in all DPR variants remains unresolved. [web:18049449][21][81]
3. Disrupted K14–K5 filament function leads to altered structural resilience and stress responses in basal keratinocytes. Filament abnormalities were observed in affected human skin; assigning every downstream effect specifically to DPR rather than the shared NFJS/DPR spectrum is partly inferred. [21][53]
4. One branch: reduced keratinocyte protection against pro-apoptotic signals leads to increased basal-cell apoptosis. Human ultrastructure supports increased apoptosis; reducing KRT14 increased TNF-α-induced apoptosis in an NFJS-related HaCaT-cell assay. Extrapolation of that cell response to every DPR lesion is inferred. [21][web:18049449]
5. Pigmentary branch: basal-layer damage and cell loss lead to pigment incontinence and dermal melanophages; these findings are proposed to contribute to persistent reticulate hyperpigmentation. The histology is observed; the complete mechanism generating its netlike distribution is not demonstrated. [21][76][122]
6. Developmental/appendage branch: altered basal-epithelial development and maintenance lead to abnormal dermatoglyphics, sweating, hair, nails, and palmoplantar keratinization. These associations are observed; the precise cell-by-cell developmental sequence is inferred. [21][52]

The landmark abstract states: “Ultrastructural examination of patient skin biopsy specimens provided evidence for increased apoptotic activity in the basal cell layer where KRT14 is expressed.” Human pathology, PMID 16960809. The mechanistic experiment’s abstract reports, “decreased KRT14 expression is associated with increased susceptibility to TNF-alpha-induced apoptosis.” In-vitro HaCaT study addressing NFJS, PMID 18049449, published online 29 November 2007 in Journal of Investigative Dermatology 2008, DOI 10.1038/sj.jid.5701187, article URL. Neither quote proves a distinct TNF-α-driven disease pathway in every person with DPR. [21][web:18049449]

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Practical diagnostic approach: recognize the childhood-onset, persistent pigment pattern and the hair–nail findings; inspect palms, soles, dermatoglyphics, sweating, teeth, and oral mucosa; document a pedigree; then seek heterozygous KRT14 sequence confirmation, particularly when NFJS, EBS, or a systemic reticulate-pigmentation disorder is plausible. A 2024 diagnostic review recommends using onset, distribution, and extracutaneous findings to reach a provisional classification while acknowledging overlap. PMID 39139099, DOI 10.1093/ced/llae322, published online 14 August 2024, article URL. [260][81][261]

There is no DPR-specific universal newborn-screening program or formally validated standalone clinical scoring criterion in these sources. Once a familial variant is established, targeted testing of relatives is feasible with genetics input. [261][52]

11. Outcome and prognosis

DPR is generally described as a lifelong disorder of skin and appendages, rather than a progressive marrow-failure or malignancy syndrome. However, there are no reliable DPR-specific five- or ten-year survival rates, life-expectancy estimates, attributable mortality rates, disability scores, or validated prognostic biomarkers. Persistent pigmentation, hair and nail changes, troublesome keratoderma, impaired sweating, and occasional blisters account for recognized morbidity. Rare ocular observations should be assessed individually rather than assumed to predict outcome. [52][59][81]

The 2024 case demonstrates a consequential diagnostic distinction: the proband’s leukemia and his mother’s tongue cancer initially raised concern for dyskeratosis congenita, but the authors found KRT14-associated DPR and stated that the family cancer history remained unexplained; cancer had not previously been established as a DPR feature. Reclassification changed counseling about prognosis and screening burden and affected the family’s psychological well-being. One family cannot establish that all carriers lack unrelated cancer risk. PMID 39106435. [81]

12. Treatment and real-world implementation

There is no established disease-modifying cure or DPR-specific treatment algorithm. Treatment is individualized to symptoms; the observations below must not be turned into response-rate claims. [39][76]

No DPR-specific gene, cell, RNA, targeted-molecular, or immunotherapy, disease-directed surgery, established pharmacogenomic rule, controlled combination regimen, response rate, or NCT-identified interventional trial was established by the disease-specific evidence reviewed here. Do not infer efficacy from EBS therapies merely because KRT14 is shared. [39][81][264]

13. Prevention

14. Other species and naturally occurring disease

15. Model organisms and experimental systems

Knowledge-base priority: curate MONDO:0007445 → KRT14 (HGNC:6416) → early truncating germline variant → basal-keratinocyte filament dysfunction/apoptotic susceptibility → ectodermal and pigmentary findings, with the phenotype HPO terms above. Keep the pigment-pattern mechanism, DPR-specific penetrance, variant-specific severity, ClinVar conflict at c.54C>A, and lack of a DPR-faithful animal model explicitly marked unresolved rather than silently converting inference into fact. [47][21][web:18049449][web:14626][264]

Reference Validation

Checked with linkml-reference-validator 0.3.0.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMC:PMC6440173 (1 mention) - Dermatopathia Pigmentosa Reticularis.
• shared terms: nail
• PMC:PMC5672609 (1 mention) - Clinical and Genetic Review of Hereditary Acral Reticulate Pigmentary Disorders.
• shared terms: pigmentation, clinical

Weighed against this report's own most characteristic terms: dpr, krt14, established, variant, phenotype, skin, nfjs, dpr-specific, disease, url, sweating, affected, pigmentation, nail, gene, family, heterozygous, hair, clinical, human.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0008404 (1 mention) - the report calls it "Onychodystrophy—brittle, short, thickened or otherwise malformed nails; clinical sign"; HP calls it Nail dystrophy**
• HP:0007455 (1 mention) - the report calls it "Adermatoglyphia, absent or poorly developed fingerprints; physical manifestation"; HP calls it Adermatoglyphia**

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0007588 (1 mention) - the report calls it "Generalized or truncal reticular hyperpigmentation; clinical sign"; HP calls it Reticular hyperpigmentation
• HP:0000972 (1 mention) - the report calls it "Palmoplantar hyperkeratosis/keratoderma; clinical sign"; HP calls it Palmoplantar hyperkeratosis**
• HP:0012788 (1 mention) - the report calls it "Reticulate oral-mucosal pigmentation; clinical sign"; HP calls it Reticulate pigmentation of oral mucosa**
• HP:0000502 (1 mention) - the report calls it "Abnormal conjunctiva morphology or other ocular finding; clinical sign"; HP calls it Abnormal conjunctiva morphology**

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: OMIM, ORPHA, MGI.